Upstream Bio Inc.
XNAS:UPB 4:00:00 PM EDT
| Market Cap (Intraday) | 450.67M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $8.64 |
| 50-Day MA | $9.27 |
| 200-Day MA | $18.48 |
Upstream Bio Inc. Stock, XNAS:UPB
890 Winter Street, Suite 200, Waltham, Massachusetts 02451
United States of America
Phone: +1.781.208.2466
Number of Employees: 52
Description
Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.